Formulation and Evaluation of Solid Lipid Nanoparticles of Olanzapine for the Treatment of Psychosis

  • Shubhangi C. Daswadkar Associate Professor, Dr. D. Y. Patil College of Pharmacy, Akurdi, Pune, Dr. D. Y. Patil Educational Complex, Sec. No. 29, Akurdi, Pune, India
  • Abhijit Vasant Atole Dept. of Pharmaceutical Quality Assurance, Dr. D. Y. Patil College of Pharmacy, Akurdi, Pune, Dr. D. Y. Patil Educational Complex, Sec. No. 29, Akurdi, Pune, India

Abstract

Solid lipid nanoparticles (SLN) are typically spherical with an average diameter between 1 nm to 1000 nm in range. It is alternative carrier systems to tradition colloidal carriers, such as liposomes emulsions and polymeric micro and nanoparticles. Olanzapine (OZP) is an atypical antipsychotic agent which is used for treatment of Schizophrenia. Its oral bioavailability is around of 40%. OZP is a class II drug so it having low aqueous solubility. To overcome that problem and to increase its bioavailability, the solid lipid nanoparticles of olanzapine are prepared. Formulation batches designed by modifying type of surfactant ( Span 80, Tween 80), concentration of surfactant, Concentration of co-surfactant, type of lipid ( glyceryl monostearate, Stearic acid), Lipid concentration, speed of stirring and time of stirring using customised design  of DOE. The SLN were prepared by high speed homogenization technique, and then characterized by particle size analysis, Drug entrapment efficiency and Drug diffusion study. A formulation containing GMS as a lipid stabilised with tween 80 as surfactant show good drug release, smaller particle size, as compared with other formulations with different lipid and surfactant. The present research findings indicate that OZP loaded solid lipid Nano particulate system for delivery of OZP with better efficacy with minimum adverse effects.


Keywords: Olanzapine, SLN, GMS, high speed homogenization and DOE.

Keywords: Olanzapine, SLN, GMS, high speed homogenization and DOE

Downloads

Download data is not yet available.

Author Biographies

Shubhangi C. Daswadkar, Associate Professor, Dr. D. Y. Patil College of Pharmacy, Akurdi, Pune, Dr. D. Y. Patil Educational Complex, Sec. No. 29, Akurdi, Pune, India

Associate Professor, Dr. D. Y. Patil College of Pharmacy, Akurdi, Pune, Dr. D. Y. Patil Educational Complex, Sec. No. 29, Akurdi, Pune, India

Abhijit Vasant Atole, Dept. of Pharmaceutical Quality Assurance, Dr. D. Y. Patil College of Pharmacy, Akurdi, Pune, Dr. D. Y. Patil Educational Complex, Sec. No. 29, Akurdi, Pune, India

Dept. of Pharmaceutical Quality Assurance, Dr. D. Y. Patil College of Pharmacy, Akurdi, Pune, Dr. D. Y. Patil Educational Complex, Sec. No. 29, Akurdi, Pune, India

References

1. https://www.who.int/mental_health/mhgap/evidence/psychosis/q1/en/
2. Ekambaram P, Sathali H, A. Abdul, Formulation and Evaluation of Solid lipid nanoparticles of Ramipril, Journal of Young pharmacists, 2011; 3(3):216-220.
3. Joseph E, Reddi S, Rinwa V, Balwani G, Saha R, Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophreniea treatment: Investigations on antipsychotic potential and adverse effects, European Journal of Pharmaceutical Sciences, 2017; 1(1):1-29.
4. Vivek K, Reddy H, Murthy RSR, “Investigations of the Effect of the Lipid Matrix on Drug Entrapment, In Vitro Release, and Physical Stability of Olanzapine-Loaded Solid Lipid Nanoparticles” AAPS PharmSciTech 2007; 8 (4):1-9.
5. Das AK, Bhanja S, Swetha T, Priyadarshini B, “Formulation and in-vitro evaluation of Olanzapine tablet for Schizophrenia and Bipolar disorder” International Journal of Pharmaceutical sciences and Research, 2014;5(1):148-155.
6. Prasanna Kumar PSS, Vijaya Kumar G, Sravani B, “Design, Formulation and In vitro evaluation of Olanzapine matrix sustained release tablets using natural polymers” World journal of Pharmacy and Pharmaceutical Science, 2017; 6(6):1442-1459.
7. Maheswarappa MK, Desai PD, “Design and in-vitro evaluation of mouth dissolving tablets of olanzapine” Asian Journal of Pharmaceutics, 2011; 5(1):107-113.
8. Gupta VN, Gowda DV, Balamuralidhara V, Mohammed Khan S, “Formulation and evaluation of olanzapine matrix pellets for controlled release” DARU, 2011; 19(4):249-256.
9. Patel RB, Patel MR, Bhatt KK, Patel BJ, Formulation and Evaluation of Microemulsions- Based drug delivery system for intranasal administration of Olanzapine, International Journal of Biomedical and Pharmaceutical Sciences, 2013; 7 (1):20-27.
10. Pandey VP, Joysa Ruby J, Formulation and evaluation of olanzapine loaded chitosan nanoparticles for nose to brain targeting an in vitro and ex vivo toxicity study, Journal of Applied Pharmaceutical Science, 2016; 6(9):034-040.
11. Sawant KK, Seju U, Kumar A, Development and Evaluation of Olanzapine loaded PLGA nanoparticles for nose to brain delivery: In vitro and In Vivo studies, Acta Biomaterialia, 2011; 7:4169-4176.
12. Kumar M, MIishra A, Mishra AK, Mishra P, Pathak K, Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting, Journal of Drug Targeting, December 2008; 16(10):806–814.
13. Abdelbary GA, Tadros MI, “Brain targeting of olanzapine via intranasal delivery of core - shell difunctional block copolymer mixed nanomicellar carriers: in-vitro characterization, ex-vivo estimation of nasal toxicity and in-vivo biodistribution studies” International Journal of Pharmaceutics, 2013; 1(1):1-51.
14. Farzaneh S, Lish SB, Abdouss M, Asadi E, Azodi-Deilami S, Khonakdar SA, Gharghabi M, Molecularly imprinted polymer nanoparticles for olanzapine recognition: application to solid phase extraction and sustained release” Royal society of chemistry advances, 2014; 1(1):1-46.
15. Vauthier C. Polymer Nanoparticles for In Vivo Applications: Progress on Preparation Methods and Future Challenges, Springer International Publishing Switzerland, 2016; 1:1-16.
16. Iqbala N, Vitorinob C, Taylora KMG. How can lipid nanocarriers improve transdermal delivery of olanzapine, Pharmaceutical Development and Technology, 2016; 1:1-11.
17. Shailaja M, Diwan PV, Ramakrishna Ramesh SG, Reddy KH, Rao YM. Development of Olanzapine Nano-Emulsion for Enhanced Brain Delivery, International Journal of Pharmaceutical Sciences and Nanotechnology, 2012; 5(1):1648-1659.
18. Natarajan J, Baskaran M, Humtose LC, Vadivelan R, Justin A. Enhanced brain targeting efficacy of olanzapine through solid lipid nanoparticles, Journal of artificial cells, nanomedicine, and biotechnology, 2017; 45(2):1-23.
19. Ekambaram P, Abdul Hasan Sathali A, Priyanka K. A review of Solid Lipid Nanoparticles, Journal of Scientific Reviews and Chemical Communications, 2012; 2(1):80-102.
Statistics
0 Views | 0 Downloads
How to Cite
1.
Daswadkar SC, Atole AV. Formulation and Evaluation of Solid Lipid Nanoparticles of Olanzapine for the Treatment of Psychosis. JDDT [Internet]. 15Oct.2020 [cited 21Oct.2020];10(5-s):25-1. Available from: http://jddtonline.info/index.php/jddt/article/view/4440